MedCana, a leading global infrastructure holding company focused on the pharmaceutical-grade cannabis industry, has entered negotiations with an Australian pharmaceutical firm to supply medical-grade cannabis through one of its subsidiaries in Colombia.
The agreement is projected to provide between $100,000 to $200,000 in monthly revenue once operations begin.
“This agreement represents a pivotal moment for MedCana as we continue expanding globally to meet the increasing demand for pharmaceutical-grade cannabis,” MedCana CEO Jose Gabriel Diaz said.
H/T: www.cannabisbusinesstimes.com